<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934791</url>
  </required_header>
  <id_info>
    <org_study_id>08-004315</org_study_id>
    <nct_id>NCT00934791</nct_id>
  </id_info>
  <brief_title>Polycystic Liver Disease in Kidney Transplant</brief_title>
  <official_title>Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if one kind of immunosuppressive drug has better effects
      for the patient's polycystic liver disease than another type. Tacrolimus and Sirolimus are
      the two immunosuppressive drugs that will be compared for this study. Both drugs have been
      commonly prescribed to prevent rejection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening monogenic disease
      with a prevalence of 1 in 400-1000 livebirths. ADPKD is caused by mutations to polycystic
      kidney disease 1 gene (PKD1) (approximately 85% of cases) or polycystic kidney disease 2 gene
      (PKD2) (the remaining 15%) gene, encoding polycystin-1 (PC1) and polycystin-2 (PC2),
      respectively. PC1 is a putative cell-surface, receptor-like protein with yet to-be-identified
      ligand(s), and PC2 a channel protein with a high conductance to Ca2+.

      Polycystic liver disease (PLD) is the most common extra-renal manifestation in ADPKD, present
      in &gt; 90% of ADPKD patients by age 30. Liver cysts in ADPKD originate from biliary
      micro-hamartoma or focal proliferations of biliary ductules and from peribiliary glands.
      Excessive proliferation of biliary epithelial cells, combined with neovascularization,
      altered cell-extracellular matrix (ECM) interaction/ECM remodeling and cAMP-mediated fluid
      secretion, is required for the development and expansion of PLD liver cysts.

      PLD may become symptomatic with acute complications such as cyst hemorrhage, rupture and
      infection. Chronic symptoms are frequently associated with massively enlarged PLD, including
      abdominal distension and pain; dyspnea; gastroesophageal reflux and early satiety which may
      lead to malnutrition; mechanical lower back pain; obstruction of the inferior vena cava,
      hepatic and portal veins (leading to dialysis-associated hypotension, hepatic venous outflow
      obstruction, and portal hypertension) and biliary obstruction. Currently, apart from invasive
      interventions such as cyst aspiration with sclerosis, cyst fenestration combined hepatic
      resection and cyst fenestration, liver transplantation and, rarely, selective hepatic artery
      embolization, no medical therapy is available.

      The objective of this study is to conduct a prospective, open-label, randomized trial to
      examine the effect of sirolimus on total liver volume in kidney transplant recipients with
      ADPKD.

      Four weeks following kidney transplant, subjects will undergo iothalamate clearance
      measurement, 24-hour urine collection and protein measurement and physical examination by a
      transplant surgeon. Patients will be randomized to receive either sirolimus-based
      immunosuppression or to continue tacrolimus-based immunosuppression unless one of the
      following conditions are noted:

        1. Complications of the kidney transplant incision, including, but not limited to:
           superficial wound infection, deep wound infection, and fascial dehiscence

        2. Iothalamate clearance measurement less than 40 mL/min/1.72m^2

        3. Urinary protein excretion greater than 800 mg/24 hours. Subjects with the above
           conditions will continue to receive tacrolimus-based immunosuppression at the discretion
           of the treating physician/surgeon.

      Enrolled subjects will undergo abdominal and pelvic CT scans within 3 months before or after
      kidney transplantation and at one, two, and three years after kidney transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to inadequate enrollment
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver Volume at 2 Years After Kidney Transplantation</measure>
    <time_frame>2 years</time_frame>
    <description>Liver volume at 2 years will be compared between the sirolimus and control (tacrolimus) groups using analysis of covariance (ANCOVA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus, mycophenolate mofetil, and prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus, mycophenolate mofetil, and prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)</description>
    <arm_group_label>Sirolimus Group</arm_group_label>
    <other_name>Rapamune</other_name>
    <other_name>Rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Mycophenolate Mofetil 750 mg twice daily</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Sirolimus Group</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone tapered to 5 mg/day by day 92</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Sirolimus Group</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (&gt; 18 years old) with stage IV or V chronic kidney due to ADPKD

          -  Primary kidney transplant

          -  Living or deceased donor kidney transplant

          -  Estimate total liver volume of 2.5 to 7.5 L

          -  In addition, at the discretion of the principal investigator(s), certain subjects with
             numerous liver cysts but with liver volume &lt; 2.5 liters may be enrolled.

        Exclusion Criteria:

          -  Pediatric patients (&lt; 18 years of age)

          -  Patients with Body Mass Index (BMI) greater than or equal to 40 kg/m^2

          -  Multi-organ transplant (kidney-liver, etc.)

          -  When people who have one blood type receive blood from someone with a different blood
             type, it may cause their immune system to react. This is called (ABO) incompatibility.
             ABO-incompatible or positive cross-match recipients

          -  Patients with severe hyperlipidemia (serum cholesterol &gt; 350 mg/dl or serum
             triglycerides &gt; 500 mg/dl)

          -  Patients with leukopenia (WBC &lt; 3000 10/ml)

          -  Patients unwilling to return to the transplant center for late follow-up visits

          -  Patients who are currently pregnant or breast-feeding or who expect to be pregnant
             during the study period

          -  Female patients of child bearing potential and men with sexual partners of child
             bearing potential who do not agree to use a medically accepted method of contraception
             during the study period

          -  Patients who are not eligible for Thymoglobulin induction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Dean, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>QI Qian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <results_first_submitted>February 4, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2013</results_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Patrick G. Dean</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplant</keyword>
  <keyword>Autosomal dominant polycystic kidney disease</keyword>
  <keyword>Polycystic liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two participants were enrolled in the study in Rochester, Minnesota. One participant withdrew before doing any part of the study; he was not randomized to a group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Tacrolimus, mycophenolate mofetil, and prednisone</description>
        </group>
        <group group_id="P2">
          <title>Sirolimus Group</title>
          <description>Sirolimus, mycophenolate mofetil, and prednisone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Tacrolimus, mycophenolate mofetil, and prednisone</description>
        </group>
        <group group_id="B2">
          <title>Sirolimus Group</title>
          <description>Sirolimus, mycophenolate mofetil, and prednisone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver Volume at 2 Years After Kidney Transplantation</title>
        <description>Liver volume at 2 years will be compared between the sirolimus and control (tacrolimus) groups using analysis of covariance (ANCOVA).</description>
        <time_frame>2 years</time_frame>
        <population>This study was terminated due to inadequate enrollment, no data was collected on the participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Tacrolimus, mycophenolate mofetil, and prednisone</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus Group</title>
            <description>Sirolimus, mycophenolate mofetil, and prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Volume at 2 Years After Kidney Transplantation</title>
          <description>Liver volume at 2 years will be compared between the sirolimus and control (tacrolimus) groups using analysis of covariance (ANCOVA).</description>
          <population>This study was terminated due to inadequate enrollment, no data was collected on the participant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Tacrolimus, mycophenolate mofetil, and prednisone</description>
        </group>
        <group group_id="E2">
          <title>Sirolimus Group</title>
          <description>Sirolimus, mycophenolate mofetil, and prednisone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated due to inadequate enrollment, no data was collected on the participant.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Patrick G. Dean</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-6953</phone>
      <email>dean.patrick2@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

